Evidence map›Paper›PMID 37161569›Full record

ArticleRespiratory research2023

A fully automated micro‑CT deep learning approach for precision preclinical investigation of lung fibrosis progression and response to therapy.

Martina Buccardi, Erica Ferrini, Francesca Pennati, Elena Vincenzi, Roberta Eufrasia Ledda, Andrea Grandi, Davide Buseghin, Gino Villetti, Nicola Sverzellati, Andrea Aliverti and 1 more

Open access · goldAbstract read
In one paragraph

Article in Respiratory research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Frontiers in pharmacology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Martina Buccardi *Department of Mathematical, Physical and Computer Sciences, University of Parma, Parma, Italy.
Erica Ferrini *Department of Veterinary Science, University of Parma, Parma, Italy.
Francesca PennatiDipartimento di Elettronica, Informazione e Bioingegneria, Politecnico Di Milano, Milan, Italy.
Elena VincenziDepartment of Computer Science, Bioengineering, Robotics and Systems Engineering, University of Genoa, Genoa, Italy.
Roberta Eufrasia LeddaDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Andrea GrandiExperimental Pharmacology & Translational Science Department, Chiesi Farmaceutici S.P.A, 43122, Parma, Italy.
Davide BuseghinDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Gino VillettiExperimental Pharmacology & Translational Science Department, Chiesi Farmaceutici S.P.A, 43122, Parma, Italy.
Nicola SverzellatiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Andrea AlivertiDipartimento di Elettronica, Informazione e Bioingegneria, Politecnico Di Milano, Milan, Italy.
Franco Fabio StellariExperimental Pharmacology & Translational Science Department, Chiesi Farmaceutici S.P.A, 43122, Parma, Italy. fb.stellari@chiesi.com.ORCID http://orcid.org/0000-0002-8855-7297
University of Parma · ITChiesi Foundation · ITPolitecnico di Milano · ITCamelot Biomedical Systems (Italy) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Micro-computed tomography (µCT)-based imaging plays a key role in monitoring disease progression and response to candidate drugs in various animal models of human disease, but manual image processing is still highly time-consuming and prone to operator bias. Focusing on an established mouse model of bleomycin (BLM)-induced lung fibrosis we document, here, the ability of a fully automated deep-learning (DL)-based model to improve and speed-up lung segmentation and the precise measurement of morphological and functional biomarkers in both the whole lung and in individual lobes. µCT-DL whose results were overall highly consistent with those of more conventional, especially histological, analyses, allowed to cut down by approximately 45-fold the time required to analyze the entire dataset and to longitudinally follow fibrosis evolution and response to the human-use-approved drug Nintedanib, using both inspiratory and expiratory μCT. Particularly significant advantages of this µCT-DL approach, are: (i) its reduced experimental variability, due to the fact that each animal acts as its own control and the measured, operator bias-free biomarkers can be quantitatively compared across experiments; (ii) its ability to monitor longitudinally the spatial distribution of fibrotic lesions, thus eliminating potential confounding effects associated with the more severe fibrosis observed in the apical region of the left lung and the compensatory effects taking place in the right lung; (iii) the animal sparing afforded by its non-invasive nature and high reliability; and (iv) the fact that it can be integrated into different drug discovery pipelines with a substantial increase in both the speed and robustness of the evaluation of new candidate drugs. The µCT-DL approach thus lends itself as a powerful new tool for the precision preclinical monitoring of BLM-induced lung fibrosis and other disease models as well. Its ease of operation and use of standard imaging instrumentation make it easily transferable to other laboratories and to other experimental settings, including clinical diagnostic applications.

Indexed as

Deep LearningPulmonary FibrosisAnimalsBleomycinDisease Models, AnimalHumansMiceReproducibility of ResultsX-Ray MicrotomographyBleomycinBleomycin modelDeep learningDrug discoveryLung fibrosisMicro-computed tomography

Identifiers

PMID37161569
PMCPMC10170869
OpenAlexW4376115774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.